ClinicalTrials.gg
CompletedNCT01976364OPAL BALANCEUpdated May 21, 2020Results posted

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

A Phase 3 interventional study of Tofacitinib and Tofacitinib in Arthritis, Psoriatic, sponsored by Pfizer. Completed at 153 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-21.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
686
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing tofacitinib in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. tofacitinib · Arthritis, Psoriatic.

Enrollment
2nd of 10
686 · median 237
Started
2014
with 1 other
Phase 3
7 of 10
1 open now
Registered
4th of 10
by date
Lead sponsor
5 of 10
Pfizer

Among the 10 studies testing tofacitinib in Arthritis, Psoriatic, this one is the 2nd largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 3, and was the 4th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 10 studies testing tofacitinib in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing tofacitinib in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability and efficacy of tofacitinib in subjects with active PsA who have previously participated in randomized studies of tofacitinib for this indication.

This study will include a sub-study to evaluate the efficacy, safety and tolerability of tofacitinib 5 mg BID administered as monotherapy after methotrexate withdrawal compared to tofacitinib 5 mg BID continued in combination with methotrexate. The sub-study will be available to subjects who have completed at least 24 months of participation in the open-label extension study and meet eligibility criteria for the sub-study.

03

Conditions studied

  • Arthritis, Psoriatic

Keywords

  • Tofacitinib
  • Psoriatic Arthritis
  • Xeljanz
  • CP-690550
  • Jak-inhibitor
  • oral treatment
  • psoriasis
  • OPAL BALANCE
  • methotrexate
  • pruritus
  • itch
  • DLQI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previous participation in qualifying PsA study involving tofacitinib

Exclusion criteria

Exclusion Criteria:

  • Time from End of Study visit of qualifying study is >3 months.
  • Pregnant female, breastfeeding female or female of unwilling or unable to use highly effective for duration of study and one ovulatory cycle thereafter.

Sub-study Inclusion Criteria:

  • Subjects who have completed at least 24 months of treatment with tofacitinib in the extension study
  • Subjects on a stable oral dose of methotrexate (maximum dose 20 mg per week)

Sub-study Exclusion Criteria:

-Subjects who are receiving methotrexate by a route other than oral

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
686 participants (actual)

Study arms

  • Experimental
    Tofacitinib

    Drug: Tofacitinib · Drug: Methotrexate · Drug: Placebo Methotrexate

Interventions

  • Tofacitinib 5 mg tablet twice daily

  • Tofactinib 10 mg tablet twice daily

  • Methotrexate 7.5-20 mg weekly

    Also known as: Sub-study

  • DrugPlacebo Methotrexate

    Placebo to match active methotrexate orally once a week

    Also known as: Sub-study

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 48 months that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.

    Time frame: Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)

  2. Number of Adverse Events (AEs) by Severity

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified into 3 categories according to their severity as mild AEs (did not interfere with participant's usual function), moderate AEs (interfered to some extent with participant's usual function) and severe AEs (interfered significantly with participant's usual function).

    Time frame: Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)

  3. Number of Participants With Abnormal Clinical Laboratory Values

    Laboratory tests: hematology (Hb, hematocrit, RBC count, platelets, reticulocytes, WBC count, count and absolute lymphocytes,neutrophils, basophils, eosinophils, monocytes. Liver function (bilirubin \[total, direct, indirect\], AST, ALT, alkaline phosphatase, gamma-glutamyl transferase, albumin, total protein), renal function (blood urea nitrogen, creatinine), Lipids (cholesterol, HDL, LDL, triglyceride, apolipoprotein \[A-1, B\]), electrolytes (sodium, potassium, chloride, calcium, biocarbonate), chemistry (glucose, HbA1c, creatinine kinapse), urinalysis dipstick(urine pH, glucose, ketones, protein, blood, leukocyte, esterase), urinalysis microscopy (urine- RBC, WBC, bacteria, epithelial cells),C-reactive protein. Laboratory abnormality: determined by investigator per pre-defined criteria.

    Time frame: Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)

  4. Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values

    Laboratory tests: hematology (Hb, hematocrit, RBC count, platelets, reticulocytes, WBC count, count and absolute lymphocytes, neutrophils, basophils, eosinophils, monocytes. Liver function (bilirubin\[total,direct,indirect\], AST, ALT, alkaline phosphatase, gamma-glutamyl transferase, albumin, total protein), renal function (blood urea nitrogen, creatinine), Lipids(cholesterol, HDL, LDL, triglyceride, apolipoprotein \[A-1, B\]), electrolytes (sodium, potassium, chloride, calcium, biocarbonate), chemistry (glucose, HbA1c, creatinine kinapse), urinalysis dipstick(urine-pH, glucose, ketones, protein, blood, leukocyte, esterase), urinalysis microscopy(urine- RBC, WBC, bacteria, epithelial cells),C-reactive protein. Clinically significant change: determined by investigator per pre-defined criteria.

    Time frame: Date of first dose of study medication (Baseline) up to 48 months (36 months of main study and 12 months of sub-study)

  5. Sub-study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Month 6

    HAQ-DI assessed the degree of difficulty a participant had experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible HAQ-DI score ranged from 0 (least difficulty) to 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.

    Time frame: Sub-study: Baseline (Day 1), Month 6

  6. Sub-study: Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6

    PASDAS was composite PsA disease activity score that included following components: Physician and patient global assessment of disease activity (assessed on a 0-100 VAS) in millimeter (mm), swollen (66 joints) and tender joint counts (68 joints), Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6), tender dactylitic digit score (scored on a scale of 0-3, where 0= no tenderness and 3= extreme tenderness), short form-36 questionnaire (SF-36) physical component summary (norm-based domain scores were used in analyses; with a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity) and C-reactive protein (CRP) in milligram per liter (mg/L). PASDAS was composite score and was a weighted index with score range of 0 to 10, where higher score indicated more severe disease.

    Time frame: Sub-study: Baseline (Day 1), Month 6

Secondary outcomes

  1. Main Study: Percentage of Participants Achieving an American College of Rheumatology 20 Percent (%) (ACR20) Response

    Participants with 20% improvement from baseline in tender and swollen joint counts and 20% improvement in at least 3 of the 5 measures: Patient's global assessment of arthritis (PtGA), Physician's global assessment of arthritis (PhyGA), participant's assessment of arthritis pain, HAQ-DI and C-reactive protein (CRP) in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

    Time frame: Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  2. Main Study: Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response

    Participants with 50% improvement from baseline in tender and swollen joint counts and 50% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

    Time frame: Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  3. Main Study: Percentage of Participants Achieving an American College of Rheumatology 70% (ACR70) Response

    Participants with 70% improvement from baseline in tender and swollen joint counts and 70% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

    Time frame: Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  4. Main Study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

    HAQ-DI assessed the degree of difficulty a participant had experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain score and divided by the number of domains answered. Total possible HAQ-DI score range 0 (least difficulty) and 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.

    Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  5. Main Study: Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)

    PsARC is comprised of 4 clinical improvement criteria: greater than or equal to (\>=) 20% improvement in PhyGA (VAS), \>=20% improvement in PtGA; and \>= 30% reduction in the number of tender joints; and \>=30% reduction in the number of swollen joints. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. To achieve a clinical response, the participant must improve in 2 of the 4 PsARC criteria, 1 of which has to be the number of tender or swollen joints and none of the 4 score could worsen.

    Time frame: Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  6. Main Study: Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Score (For Participants With Baseline PGA-PsO Score Greater Than [>]0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

    The PGA-PsO was a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0-4). Higher score indicated higher disease severity. Severity score for each erythema, induration and scaling were summed and averaged after which the total average was rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0= clear, except for any residual discoloration, 1= almost clear, 2= mild, 3= moderate, 4= severe).

    Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  7. Main Study: Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Score (For Participants With Baseline Body Surface Area [BSA]>=3% and Baseline PASI Score >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

    PASI: combined assessment of lesion severity and body area affected into single score; range =0 (no disease) -72 (maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0 (0%) - 6 (90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1 =slight, 2 =moderate, 3 =marked, 4 =very marked. Final PASI =sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI75: at least a 75 % reduction in PASI relative to Baseline.

    Time frame: Main study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  8. Main Study: Percent Change From Baseline in PASI Composite Score (For Participants With Baseline BSA>=3% and Baseline PASI Score >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

    PASI: combined assessment of lesion severity \& area affected into single score; range=0(no disease)-72(maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0(0%) - 6(90-100%) \& severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).

    Time frame: Main study: Baseline, Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  9. Main Study: Percent Change From Baseline in PASI Clinical Signs Component Score (For Participants With Baseline BSA>=3% and Baseline PASI Score >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

    PASI: combined assessment of lesion severity \& area affected into single score; range=0(no disease)-72(maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of clinical sign components for erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0(0%) - 6(90-100%) and severity estimated by clinical signs components for erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).

    Time frame: Main study: Baseline(Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  10. Main Study: Change From Baseline in Dactylitis Severity Score (DSS) (For Participants With Baseline DSS Greater Than [>] 0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

    Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis severity score for a participant was 0-60. Higher score indicated greater severity.

    Time frame: Main study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  11. Main Study: Change From Baseline in Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

    Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.

    Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  12. Main Study: Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index (For Participants With Baseline SPARCC Enthesitis Index >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

    The SPARCC enthesitis index identifies the presence or absence of tenderness at 16 enthesial sites, including (right and left): medial epicondyle humerus, lateral epicondyle humerus, supraspinatus insertion into greater tuberosity of humerus, greater trochanter, quadriceps insertion into superior border of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle, Achilles tendon insertion into calcaneum and plantar fascia insertion into calcaneum. On examination, tenderness was recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicated a greater number of sites that are affected by enthesitis.

    Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  13. Main Study: Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (For Participants With Presence of Spondylitis at Screening and Baseline BASDAI Score >0 cm) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

    BASDAI was a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 cm (0= none and 10= very severe) participants answered 6 questions pertaining to 5 symptoms including fatigue, spinal pain, joint pain/swelling, areas of localized tenderness and morning stiffness. The final BASDAI score was an average of answers to 6 questions, with an overall possible score range of 0 to 10 centimeter (cm) with higher score represented more severe ankylosing spondylitis disease activity.

    Time frame: Main study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  14. Main Study: Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (For Participants With Presence of Spondylitis at Screening and Baseline BASDAI Score >=4 cm) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

    BASDAI was a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 cm (0= none and 10= very severe) participants answered 6 questions pertaining to 5 symptoms including fatigue, spinal pain, joint pain/swelling, areas of localized tenderness and morning stiffness. The final BASDAI score was an average of answers to 6 questions, with an overall possible score range of 0 to 10 cm with higher score represented more severe ankylosing spondylitis disease activity.

    Time frame: Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

  15. Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Component Summary Score at Months 1, 6, 12, 18, 24, 30 and 36

    The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 8 health domains were aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Norm-based domain scores, PCS and MCS scores were used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represented better physical health status.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  16. Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Mental Component Summary Score at Months 1, 6, 12, 18, 24, 30, and 36

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  17. Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Functioning Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

    SF-36v2 was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 10 items of the physical functioning scale represented levels and kinds of limitations between extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence and extent of physical limitations using a 3-level response continuum. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represented better physical functioning.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  18. Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Role-Physical Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

    SF-36v2 acute was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; \& d) accomplishing less. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represented better role-physical functioning.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  19. Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Bodily Pain Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

    The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represented less bodily pain.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  20. Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) General Health Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

    The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consisted of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher general health domain score represented better general health perceptions.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  21. Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Vitality Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher vitality domain score represents better vitality.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  22. Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Social Functioning Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

    The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assessed health-related effects on quantity and quality of social activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher social functioning domain score represented better social functioning.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  23. Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2 ) Role-Emotional Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

    The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assessed mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher role-emotional domain score represented better role-emotional functioning.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  24. Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2 ) Mental Health Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

    The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher mental health domain score represented better mental health functioning.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  25. Main Study: Change From Baseline in EuroQol- 5D Health Questionnaire 3-Level (EQ-5D-3L) Mobility Domain at Months 1, 6, 12, 18, 24, 30 and 36

    EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L mobility domain score were reported in this outcome measure.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30 and 36

  26. Main Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Self-Care Domain at Months 1, 6, 12, 18, 24, 30 and 36

    EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L self-care domain score were reported in this measure.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  27. Main Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Usual Activities Domain at Months 1, 6, 12, 18, 24, 30 and 36

    EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L usual activities domain score were reported in this measure.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  28. Main Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Pain/Discomfort Domain at Months 1, 6, 12, 18, 24, 30 and 36

    EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L pain/discomfort domain score were reported in this measure.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  29. Main Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Anxiety/Depression Domain at Months 1, 6, 12, 18, 24, 30 and 36

    EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L anxiety/depression domain score were reported in this outcome measure.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  30. Main Study: Change From Baseline in EuroQol - Visual Analog Scale (EQ-VAS) Your Own Health State Today Domain at Months 1, 6, 12, 18, 24, 30 and 36

    The EQ VAS recorded the participant's self-rated health on a vertical VAS as standard vertical 0 (worst imaginable health state) to 100 mm (best imaginable health state) (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher score indicated a better health state.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  31. Main Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Months 1, 6, 12, 18, 24, 30 and 36

    FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52):calculated by summing 13 items,higher score indicated lower level of fatigue, better participant status. All responses were added with equal weight to get total score.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  32. Main Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Experience Domain Score at Months 1, 6, 12, 18, 24, 30 and 36

    FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  33. Main Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Impact Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

    FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.

    Time frame: Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36

  34. Sub-study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Months 1, 3, 9 and 12

    HAQ-DI assessed the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain score and divided by the number of domains answered. Total possible HAQ-DI score range 0 (least difficulty) and 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 9 and 12

  35. Sub-study: Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Months 1, 3, 9 and 12

    PASDAS was composite PsA disease activity score that included following components: Physician and patient global assessment of disease activity (assessed on a 0-100 VAS) in mm, swollen (66 joints) and tender joint counts (68 joints), Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6), tender dactylitic digit score (scored on a scale of 0-3, where 0= no tenderness and 3= extreme tenderness), SF-36 physical component summary (norm-based domain score were used in analyses; with a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity) and CRP in mg/L. PASDAS was composite score and was a weighted index with score range of 0 to 10, where higher score indicated more severe disease.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 9 and 12

  36. Sub-study: Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC) at Months 1, 3, 6, 9 and 12

    PsARC was comprised of 4 clinical improvement criteria: \>=20% improvement in PhyGA (VAS), \>=20% improvement in PtGA; and \>= 30% reduction in the number of tender joints; and \>=30% reduction in the number of swollen joints. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. To achieve a clinical response, the participant must improve in 2 of the 4 PsARC criteria, 1 of which has to be the number of tender or swollen joints and none of the 4 score could worsen.

    Time frame: Months 1, 3, 6, 9 and 12

  37. Sub-study: Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Score (For Participants With Baseline PGA-PsO Score >0 ) at Months 1, 3, 6, 9 and 12

    The PGA-PsO is a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0-4). Higher score indicated higher disease severity. Severity score for each erythema, induration and scaling were summed and averaged after which the total average was rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0= clear, except for any residual discoloration, 1= almost clear, 2= mild, 3= moderate, 4= severe).

    Time frame: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  38. Sub-study: Percent Change From Baseline in Body Surface Area (BSA) (For Participants With BSA >0%) Psoriasis at Months 1, 3, 6, 9 and 12

    Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage (Head and neck = 10 handprints \[1 handprint =10%\], upper extremities = 20 handprints \[1 handprint =5%\], Trunk (including axillae and groin) = 30 handprints \[1 handprint =3.33%\], lower extremities (including buttocks) = 40 handprints \[1 handprint =2.5%\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  39. Sub-study: Change From Baseline in Dactylitis Severity Score (DSS) (For Participants With Baseline DSS >0) at Months 1, 3, 6, 9 and 12

    Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis score for a participant was 0-60. Higher score indicated greater degree of tenderness.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  40. Sub-study: Percentage of Participants With Absence of Dactylitis (For Participants With Baseline DSS >0) at Months 1, 3, 6, 9 and 12

    Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis score for a participant was 0-60. Higher score indicated greater degree of tenderness.

    Time frame: Sub-study: Months 1, 3, 6, 9 and 12

  41. Sub-study: Change From Baseline in Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI >0) at Months 1, 3, 6, 9 and 12

    Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  42. Sub-study: Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI =0) at Months 1, 3, 6, 9 and 12

    Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.

    Time frame: Sub-study: Months 1, 3, 6, 9 and 12

  43. Sub-study: Percentage of Participants With Absence of Enthesitis Assessed Using Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI >0) at Months 1, 3, 6, 9 and 12

    Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.

    Time frame: Sub-study: Months 1, 3, 6, 9 and 12

  44. Sub-study: Percentage of Participants With Minimal Disease Activity (MDA) at Months 1, 3, 6, 9 and 12

    A psoriatic arthritis participant was considered with minimal disease activity if participant had \>= 5 of 7 criteria: 1) tender/painful joint count less than or equals to (\<=) 1; (2) swollen joint count \<=1; (3) BSA \<=3%; (4) Patient Assessment of Arthritis Pain (VAS) \<=15 mm; (5) PtGA (VAS) \<=20 mm; (6) HAQ-DI score \<=0.5; (7) tender entheseal points (using LEI) \<=1.

    Time frame: Sub-study: Months 1, 3, 6, 9 and 12

  45. Sub-study: Change From Baseline in Tender/Painful Joint Count at Months 1, 3, 6, 9 and 12

    68 joints were assessed to determine joints that are considered tender or painful. Response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Done/Not Applicable (to be used for artificial or missing joints). The 68 joints assessed were: 1) Upper Body: temporomandibular, sternoclavicular, acromioclavicular. 2) Upper Extremity: shoulder, elbow, wrist (includes radiocarpal, carpal and carpometacarpal considered as one unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), distal interphalangeals (DIP II, III, IV, V). 3) Lower Extremity: hip, knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  46. Sub-study: Change From Baseline in Swollen Joint Count at Months 1, 3, 6, 9 and 12

    Joints were assessed for swelling using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). Sixty-six (66) joints were assessed for swelling. The 66 joints assessed were: 1) Upper Body: temporomandibular, sternoclavicular, acromioclavicular. 2) Upper Extremity: shoulder, elbow, wrist (includes radiocarpal, carpal and carpometacarpal considered as one unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), distal interphalangeals (DIP II, III, IV, V). 3) Lower Extremity: knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  47. Sub-study: Change From Baseline in Physician's Global Assessment of Arthritis (PhyGA) at Months 1, 3, 6, 9 and 12

    The investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and independent of the PtGA and Patient Assessment of Arthritis Pain. The investigator's response was recorded using a 100 mm VAS where 0 =PSA not active at all and 100 =PSA extremely active. Higher score indicated more PSA.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  48. Sub-study: Change From Baseline in Patient's Global Assessment of Arthritis (PtGA) at Months 1, 3, 6, 9 and 12

    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participant's response were recorded using a 0 - 100 mm VAS where 0 =not affected at all and 100 =extremely affected. Higher score indicated worse condition due to PSA.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  49. Sub-study: Change From Baseline in Patient's Assessment of Arthritis Pain at Months 1, 3, 6, 9 and 12

    Participants assessed the severity of their arthritis pain using a 100 mm VAS by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. Higher score indicated more severe pain.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  50. Sub-study: Change From Baseline in C-Reactive Protein (CRP) at Months 1, 3, 6, 9 and 12

    The test for CRP was a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  51. Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Component Summary Score at Months 1, 3, 6, 9 and 12

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represents better physical health status.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  52. Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Mental Component Summary Score at Months 1, 3, 6, 9 and 12

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  53. Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Functioning Domain Score at Months 1, 3, 6, 9 and 12

    SF-36v2 was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 10 items of the physical functioning scale represented levels and kinds of limitations between extremes of physical activities, including lifting \& carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence \& extent of physical limitations using a 3-level response continuum. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represented better physical functioning.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  54. Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Role Physical Domain Score at Months 1, 3, 6, 9 and 12

    SF-36v2 acute was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; \& d) accomplishing less. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represented better role-physical functioning.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  55. Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Bodily Pain Domain Score at Months 1, 3, 6, 9 and 12

    The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represented less bodily pain.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  56. Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) General Health Domain Score at Months 1, 3, 6, 9 and 12

    The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consisted of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher general health domain score represented better general health perceptions.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  57. Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Vitality Domain Score at Months 1, 3, 6, 9 and 12

    The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher vitality domain score represented better vitality.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  58. Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Social Functioning Domain Score at Months 1, 3, 6, 9 and 12

    The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assessed health-related effects on quantity and quality of social activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher social functioning domain score represented better social functioning.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  59. Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Role Emotional Domain Score at Months 1, 3, 6, 9 and 12

    The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assessed mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher role-emotional domain score represented better role-emotional functioning.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  60. Sub Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Mental Health Domain Score at Months 1, 3, 6, 9 and 12

    The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher mental health domain score represented better mental health functioning.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  61. Sub Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Months 1, 3, 6, 9 and 12

    FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52):calculated by summing 13 items,higher score indicated lower level of fatigue, better participant status. All responses were added with equal weight to get total score.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  62. Sub Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Experience Domain Score at Months 1, 3, 6, 9 and 12

    FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  63. Sub Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Impact Domain Score at Months 1, 3, 6, 9 and 12

    FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  64. Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Mobility Domain at Months 1, 3, 6, 9 and 12

    EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L mobility domain score were reported in this measure.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  65. Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Self-Care Domain at Months 1, 3, 6, 9 and 12

    EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L self-care domain score were reported in this measure.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  66. Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Usual Activities Domain at Months 1, 3, 6, 9 and 12

    EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L usual activities domain score were reported in this measure.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  67. Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Pain/Discomfort Domain

    EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L pain/discomfort domain score were reported in this measure.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  68. Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Anxiety/Depression Domain at Months 1, 3, 6, 9 and 12

    EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L anxiety/depression domain score were reported in this measure.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

  69. Sub Study: Change From Baseline in EuroQol - Visual Analog Scale (EQ-VAS) Your Own Health State Today Domain at Months 1, 3, 6, 9 and 12

    The EQ VAS recorded the participant's self-rated health on a vertical VAS as standard verticle 0 (worst imaginable health state) to 100 mm (best imaginable health state) (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher score indicated a better health state.

    Time frame: Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12

07

Results

Posted May 21, 2020

Participant flow

Eligible participants (who had previously participated in randomized psoriatic arthritis \[PsA\] clinical studies with tofacitinib) from qualifying studies A3921091 (NCT01877668) and A3921125 (NCT01882439) were enrolled into this current study A3921092 (NCT01976364).

Main Study (36 Months)
Participant flow — Main Study (36 Months)
MilestoneTofacitinibTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Started68600
Completed46500
Not completed22100
Withdrew: Adverse event6300
Withdrew: Withdrawn due to pregnancy500
Withdrew: Other1300
Withdrew: No longer met eligibility criteria200
Withdrew: Medication error100
Withdrew: Lost to follow-up1000
Withdrew: Lack of efficacy4000
Withdrew: Protocol violation1300
Withdrew: Withdrawal by subject6900
Withdrew: Death500
Sub-study (12 Months)
Participant flow — Sub-study (12 Months)
MilestoneTofacitinibTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Started08990
Completed08385
Not completed065
Withdrew: Lost to follow-up010
Withdrew: Withdrawal by subject001
Withdrew: Protocol violation011
Withdrew: Adverse event043

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 48 months that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.

Time frame:
Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsAll Participants
AEs83.7
SAEs16.8
PrimaryNumber of Adverse Events (AEs) by Severity

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified into 3 categories according to their severity as mild AEs (did not interfere with participant's usual function), moderate AEs (interfered to some extent with participant's usual function) and severe AEs (interfered significantly with participant's usual function).

Time frame:
Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)
Reported as:
Number · adverse events
Number of Adverse Events (AEs) by Severity
adverse eventsAll Participants
Number of adverse events: Mild1632
Number of adverse events: Moderate1045
Number of adverse events: Severe136
PrimaryNumber of Participants With Abnormal Clinical Laboratory Values

Laboratory tests: hematology (Hb, hematocrit, RBC count, platelets, reticulocytes, WBC count, count and absolute lymphocytes,neutrophils, basophils, eosinophils, monocytes. Liver function (bilirubin \[total, direct, indirect\], AST, ALT, alkaline phosphatase, gamma-glutamyl transferase, albumin, total protein), renal function (blood urea nitrogen, creatinine), Lipids (cholesterol, HDL, LDL, triglyceride, apolipoprotein \[A-1, B\]), electrolytes (sodium, potassium, chloride, calcium, biocarbonate), chemistry (glucose, HbA1c, creatinine kinapse), urinalysis dipstick(urine pH, glucose, ketones, protein, blood, leukocyte, esterase), urinalysis microscopy (urine- RBC, WBC, bacteria, epithelial cells),C-reactive protein. Laboratory abnormality: determined by investigator per pre-defined criteria.

Time frame:
Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Laboratory Values
ParticipantsAll Participants
Number of Participants With Abnormal Clinical Laboratory Values646
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values

Laboratory tests: hematology (Hb, hematocrit, RBC count, platelets, reticulocytes, WBC count, count and absolute lymphocytes, neutrophils, basophils, eosinophils, monocytes. Liver function (bilirubin\[total,direct,indirect\], AST, ALT, alkaline phosphatase, gamma-glutamyl transferase, albumin, total protein), renal function (blood urea nitrogen, creatinine), Lipids(cholesterol, HDL, LDL, triglyceride, apolipoprotein \[A-1, B\]), electrolytes (sodium, potassium, chloride, calcium, biocarbonate), chemistry (glucose, HbA1c, creatinine kinapse), urinalysis dipstick(urine-pH, glucose, ketones, protein, blood, leukocyte, esterase), urinalysis microscopy(urine- RBC, WBC, bacteria, epithelial cells),C-reactive protein. Clinically significant change: determined by investigator per pre-defined criteria.

Time frame:
Date of first dose of study medication (Baseline) up to 48 months (36 months of main study and 12 months of sub-study)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values
ParticipantsAll Participants
Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values9
PrimarySub-study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Month 6

HAQ-DI assessed the degree of difficulty a participant had experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible HAQ-DI score ranged from 0 (least difficulty) to 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.

Time frame:
Sub-study: Baseline (Day 1), Month 6
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Month 6
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Sub-study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Month 60.0174 ± 0.027750.0428 ± 0.02714
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Least squares (ls) mean difference: 0.0255 · 95% CI -0.0513 to 0.1022
PrimarySub-study: Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6

PASDAS was composite PsA disease activity score that included following components: Physician and patient global assessment of disease activity (assessed on a 0-100 VAS) in millimeter (mm), swollen (66 joints) and tender joint counts (68 joints), Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6), tender dactylitic digit score (scored on a scale of 0-3, where 0= no tenderness and 3= extreme tenderness), short form-36 questionnaire (SF-36) physical component summary (norm-based domain scores were used in analyses; with a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity) and C-reactive protein (CRP) in milligram per liter (mg/L). PASDAS was composite score and was a weighted index with score range of 0 to 10, where higher score indicated more severe disease.

Time frame:
Sub-study: Baseline (Day 1), Month 6
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Sub-study: Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 60.138 ± 0.08050.229 ± 0.0786
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.091 · 95% CI -0.131 to 0.313
SecondaryMain Study: Percentage of Participants Achieving an American College of Rheumatology 20 Percent (%) (ACR20) Response

Participants with 20% improvement from baseline in tender and swollen joint counts and 20% improvement in at least 3 of the 5 measures: Patient's global assessment of arthritis (PtGA), Physician's global assessment of arthritis (PhyGA), participant's assessment of arthritis pain, HAQ-DI and C-reactive protein (CRP) in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

Time frame:
Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving an American College of Rheumatology 20 Percent (%) (ACR20) Response
percentage of participantsTofacitinib
Month 166.12 (62.55 to 69.70)
Month 368.79 (65.25 to 72.32)
Month 670.66 (67.12 to 74.21)
Month 971.48 (67.87 to 75.08)
Month 1274.18 (70.62 to 77.74)
Month 1578.04 (74.58 to 81.50)
Month 1877.65 (74.13 to 81.18)
Month 2177.00 (73.40 to 80.59)
Month 2476.13 (72.43 to 79.82)
Month 2778.18 (74.54 to 81.82)
Month 3080.79 (77.27 to 84.32)
Month 3377.88 (74.05 to 81.70)
Month 3677.02 (72.81 to 81.24)
SecondaryMain Study: Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response

Participants with 50% improvement from baseline in tender and swollen joint counts and 50% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

Time frame:
Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response
percentage of participantsTofacitinib
Month 145.70 (41.94 to 49.46)
Month 343.27 (39.49 to 47.04)
Month 647.08 (43.19 to 50.97)
Month 950.41 (46.43 to 54.40)
Month 1250.26 (46.19 to 54.32)
Month 1555.42 (51.28 to 59.55)
Month 1855.10 (50.90 to 59.30)
Month 2155.41 (51.16 to 59.65)
Month 2457.34 (53.05 to 61.63)
Month 2756.05 (51.68 to 60.42)
Month 3060.46 (56.08 to 64.84)
Month 3357.96 (53.41 to 62.52)
Month 3658.85 (53.93 to 63.78)
SecondaryMain Study: Percentage of Participants Achieving an American College of Rheumatology 70% (ACR70) Response

Participants with 70% improvement from baseline in tender and swollen joint counts and 70% improvement in at least 3 of the 5 measures: PtGA, PhyGA, participant's assessment of arthritis pain, HAQ-DI and CRP in mg/L. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. Participant's assessment of arthritis pain: participant assessed pain on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.

Time frame:
Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving an American College of Rheumatology 70% (ACR70) Response
percentage of participantsTofacitinib
Month 124.85 (21.59 to 28.11)
Month 326.13 (22.79 to 29.48)
Month 630.50 (26.92 to 34.08)
Month 930.81 (27.13 to 34.48)
Month 1232.13 (28.34 to 35.92)
Month 1533.87 (29.94 to 37.81)
Month 1836.25 (32.18 to 40.31)
Month 2134.35 (30.29 to 38.40)
Month 2435.94 (31.78 to 40.09)
Month 2738.10 (33.83 to 42.38)
Month 3041.60 (37.17 to 46.02)
Month 3338.19 (33.72 to 42.66)
Month 3637.76 (32.91 to 42.61)
SecondaryMain Study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

HAQ-DI assessed the degree of difficulty a participant had experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain score and divided by the number of domains answered. Total possible HAQ-DI score range 0 (least difficulty) and 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.

Time frame:
Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
units on a scaleTofacitinib
Change at Month 1-0.4373 ± 0.55677
Change at Month 3-0.4559 ± 0.55104
Change at Month 6-0.4755 ± 0.57468
Change at Month 9-0.4841 ± 0.58294
Change at Month 12-0.4782 ± 0.60163
Change at Month 15-0.5108 ± 0.58277
Change at Month 18-0.5116 ± 0.59401
Change at Month 21-0.5211 ± 0.59568
Change at Month 24-0.5068 ± 0.62016
Change at Month 27-0.5219 ± 0.60833
Change at Month 30-0.5356 ± 0.61316
Change at Month 33-0.5276 ± 0.63803
Change at Month 36-0.5476 ± 0.65226
SecondaryMain Study: Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)

PsARC is comprised of 4 clinical improvement criteria: greater than or equal to (\>=) 20% improvement in PhyGA (VAS), \>=20% improvement in PtGA; and \>= 30% reduction in the number of tender joints; and \>=30% reduction in the number of swollen joints. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. To achieve a clinical response, the participant must improve in 2 of the 4 PsARC criteria, 1 of which has to be the number of tender or swollen joints and none of the 4 score could worsen.

Time frame:
Main Study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)
percentage of participantsTofacitinib
Month 168.46 (64.94 to 71.98)
Month 369.56 (66.04 to 73.08)
Month 673.14 (69.69 to 76.60)
Month 974.46 (70.97 to 77.95)
Month 1276.08 (72.60 to 79.56)
Month 1579.52 (76.14 to 82.91)
Month 1880.15 (76.77 to 83.53)
Month 2179.50 (76.04 to 82.96)
Month 2477.51 (73.88 to 81.15)
Month 2780.16 (76.65 to 83.68)
Month 3082.11 (78.66 to 85.55)
Month 3380.85 (77.21 to 84.49)
Month 3677.17 (72.95 to 81.38)
SecondaryMain Study: Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Score (For Participants With Baseline PGA-PsO Score Greater Than [>]0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

The PGA-PsO was a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0-4). Higher score indicated higher disease severity. Severity score for each erythema, induration and scaling were summed and averaged after which the total average was rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0= clear, except for any residual discoloration, 1= almost clear, 2= mild, 3= moderate, 4= severe).

Time frame:
Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Score (For Participants With Baseline PGA-PsO Score Greater Than [>]0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
units on a scaleTofacitinib
Change at Month 1-1.1 ± 1.04
Change at Month 3-1.1 ± 1.04
Change at Month 6-1.2 ± 1.03
Change at Month 9-1.2 ± 1.06
Change at Month 12-1.1 ± 1.06
Change at Month 15-1.2 ± 1.07
Change at Month 18-1.2 ± 1.05
Change at Month 21-1.2 ± 1.06
Change at Month 24-1.3 ± 1.02
Change at Month 27-1.3 ± 1.02
Change at Month 30-1.3 ± 1.05
Change at Month 33-1.3 ± 1.02
Change at Month 36-1.2 ± 1.02
SecondaryMain Study: Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Score (For Participants With Baseline Body Surface Area [BSA]>=3% and Baseline PASI Score >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

PASI: combined assessment of lesion severity and body area affected into single score; range =0 (no disease) -72 (maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0 (0%) - 6 (90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1 =slight, 2 =moderate, 3 =marked, 4 =very marked. Final PASI =sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI75: at least a 75 % reduction in PASI relative to Baseline.

Time frame:
Main study: Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Score (For Participants With Baseline Body Surface Area [BSA]>=3% and Baseline PASI Score >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
percentage of participantsTofacitinib
Month 155.05 (50.53 to 59.58)
Month 357.96 (53.41 to 62.52)
Month 660.74 (56.14 to 65.34)
Month 961.07 (56.36 to 65.78)
Month 1263.16 (58.42 to 67.89)
Month 1565.71 (60.95 to 70.47)
Month 1865.22 (60.35 to 70.08)
Month 2169.72 (64.98 to 74.47)
Month 2471.47 (66.72 to 76.22)
Month 2770.85 (66.04 to 75.66)
Month 3068.58 (63.58 to 73.58)
Month 3370.10 (65.01 to 75.18)
Month 3668.08 (62.41 to 73.74)
SecondaryMain Study: Percent Change From Baseline in PASI Composite Score (For Participants With Baseline BSA>=3% and Baseline PASI Score >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

PASI: combined assessment of lesion severity \& area affected into single score; range=0(no disease)-72(maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0(0%) - 6(90-100%) \& severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).

Time frame:
Main study: Baseline, Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · percent change
Main Study: Percent Change From Baseline in PASI Composite Score (For Participants With Baseline BSA>=3% and Baseline PASI Score >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
percent changeTofacitinib
At Month 1-64.09 ± 57.473
At Month 3-66.98 ± 43.647
At Month 6-68.58 ± 44.568
At Month 9-70.42 ± 40.617
At Month 12-71.58 ± 42.515
At Month 15-73.13 ± 43.653
At Month 18-73.51 ± 40.527
At Month 21-75.15 ± 44.182
At Month 24-78.36 ± 34.808
At Month 27-78.37 ± 34.405
At Month 30-78.28 ± 30.270
At Month 33-77.47 ± 43.952
At Month 36-76.85 ± 31.973
SecondaryMain Study: Percent Change From Baseline in PASI Clinical Signs Component Score (For Participants With Baseline BSA>=3% and Baseline PASI Score >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

PASI: combined assessment of lesion severity \& area affected into single score; range=0(no disease)-72(maximal disease). Higher score representing greater severity of psoriasis. PASI is a composite scoring by investigator of degree of clinical sign components for erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks). For each section % area of skin involved was estimated: 0(0%) - 6(90-100%) and severity estimated by clinical signs components for erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).

Time frame:
Main study: Baseline(Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · percent change
Main Study: Percent Change From Baseline in PASI Clinical Signs Component Score (For Participants With Baseline BSA>=3% and Baseline PASI Score >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
percent changeTofacitinib
Induration: At Month 1-62.60 ± 62.288
Induration: At Month 3-66.92 ± 46.898
Induration: At Month 6-68.63 ± 46.644
Induration: At Month 9-70.33 ± 41.960
Induration: At Month 12-70.81 ± 48.439
Induration: At Month 15-72.49 ± 48.644
Induration: At Month 18-73.16 ± 40.801
Induration: At Month 21-74.34 ± 47.617
Induration: At Month 24-78.45 ± 36.534
Induration: At Month 27-77.85 ± 34.297
Induration: At Month 30-78.55 ± 31.187
Induration: At Month 33-77.09 ± 42.305
Induration: At Month 36-76.11 ± 35.000
Erythema: At Month 1-63.60 ± 67.818
Erythema: At Month 3-66.69 ± 43.013
Erythema: At Month 6-67.17 ± 46.756
Erythema: At Month 9-69.75 ± 42.882
Erythema: At Month 12-70.45 ± 46.575
Erythema: At Month 15-71.55 ± 50.406
Erythema: At Month 18-73.12 ± 45.194
Erythema: At Month 21-75.06 ± 45.993
Erythema: At Month 24-77.40 ± 38.093
Erythema: At Month 27-77.83 ± 33.877
Erythema: At Month 30-77.04 ± 33.478
Erythema: At Month 33-75.17 ± 53.782
Erythema: At Month 36-75.72 ± 34.823
Scaling: At Month 1-64.26 ± 55.848
Scaling: At Month 3-66.15 ± 52.568
Scaling: At Month 6-68.66 ± 49.145
Scaling: At Month 9-69.09 ± 48.506
Scaling: At Month 12-72.48 ± 45.755
Scaling: At Month 15-73.83 ± 42.528
Scaling: At Month 18-74.62 ± 39.708
Scaling: At Month 21-75.11 ± 44.570
Scaling: At Month 24-77.86 ± 38.041
Scaling: At Month 27-79.34 ± 31.825
Scaling: At Month 30-77.23 ± 37.819
Scaling: At Month 33-77.94 ± 41.688
Scaling: At Month 36-78.10 ± 30.391
SecondaryMain Study: Change From Baseline in Dactylitis Severity Score (DSS) (For Participants With Baseline DSS Greater Than [>] 0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis severity score for a participant was 0-60. Higher score indicated greater severity.

Time frame:
Main study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Dactylitis Severity Score (DSS) (For Participants With Baseline DSS Greater Than [>] 0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
units on a scaleTofacitinib
Change at Month 1-6.7 ± 7.65
Change at Month 3-6.8 ± 7.71
Change at Month 6-7.2 ± 7.89
Change at Month 9-7.4 ± 7.29
Change at Month 12-7.6 ± 7.70
Change at Month 15-7.7 ± 7.44
Change at Month 18-7.7 ± 7.50
Change at Month 21-7.8 ± 7.89
Change at Month 24-7.9 ± 7.76
Change at Month 27-8.1 ± 7.59
Change at Month 30-8.0 ± 7.65
Change at Month 33-8.1 ± 7.75
Change at Month 36-7.7 ± 7.88
SecondaryMain Study: Change From Baseline in Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.

Time frame:
Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
units on a scaleTofacitinib
Change at Month 1-1.5 ± 1.88
Change at Month 3-1.6 ± 1.79
Change at Month 6-1.7 ± 1.78
Change at Month 9-1.8 ± 1.80
Change at Month 12-1.7 ± 1.82
Change at Month 15-2.0 ± 1.76
Change at Month 18-1.9 ± 1.79
Change at Month 21-1.9 ± 1.81
Change at Month 24-2.0 ± 1.72
Change at Month 27-2.0 ± 1.73
Change at Month 30-2.0 ± 1.76
Change at Month 33-2.0 ± 1.75
Change at Month 36-2.1 ± 1.76
SecondaryMain Study: Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index (For Participants With Baseline SPARCC Enthesitis Index >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

The SPARCC enthesitis index identifies the presence or absence of tenderness at 16 enthesial sites, including (right and left): medial epicondyle humerus, lateral epicondyle humerus, supraspinatus insertion into greater tuberosity of humerus, greater trochanter, quadriceps insertion into superior border of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle, Achilles tendon insertion into calcaneum and plantar fascia insertion into calcaneum. On examination, tenderness was recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicated a greater number of sites that are affected by enthesitis.

Time frame:
Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index (For Participants With Baseline SPARCC Enthesitis Index >0) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
units on a scaleTofacitinib
Change at Month 1-2.8 ± 3.60
Change at Month 3-3.0 ± 3.61
Change at Month 6-3.2 ± 3.72
Change at Month 9-3.4 ± 3.69
Change at Month 12-3.5 ± 3.46
Change at Month 15-3.7 ± 3.55
Change at Month 18-3.5 ± 3.45
Change at Month 21-3.6 ± 3.60
Change at Month 24-3.7 ± 3.62
Change at Month 27-3.7 ± 3.56
Change at Month 30-3.8 ± 3.49
Change at Month 33-3.9 ± 3.39
Change at Month 36-3.9 ± 3.69
SecondaryMain Study: Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (For Participants With Presence of Spondylitis at Screening and Baseline BASDAI Score >0 cm) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

BASDAI was a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 cm (0= none and 10= very severe) participants answered 6 questions pertaining to 5 symptoms including fatigue, spinal pain, joint pain/swelling, areas of localized tenderness and morning stiffness. The final BASDAI score was an average of answers to 6 questions, with an overall possible score range of 0 to 10 centimeter (cm) with higher score represented more severe ankylosing spondylitis disease activity.

Time frame:
Main study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · centimeter
Main Study: Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (For Participants With Presence of Spondylitis at Screening and Baseline BASDAI Score >0 cm) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
centimeterTofacitinib
Change at Month 1-2.26 ± 2.367
Change at Month 3-2.10 ± 2.278
Change at Month 6-2.40 ± 2.371
Change at Month 9-2.35 ± 2.254
Change at Month 12-2.41 ± 2.371
Change at Month 15-2.35 ± 2.547
Change at Month 18-2.41 ± 2.640
Change at Month 21-2.28 ± 2.582
Change at Month 24-2.47 ± 2.640
Change at Month 27-2.65 ± 2.658
Change at Month 30-2.95 ± 2.672
Change at Month 33-2.85 ± 2.671
Change at Month 36-2.88 ± 2.521
SecondaryMain Study: Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (For Participants With Presence of Spondylitis at Screening and Baseline BASDAI Score >=4 cm) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36

BASDAI was a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a VAS of 0-10 cm (0= none and 10= very severe) participants answered 6 questions pertaining to 5 symptoms including fatigue, spinal pain, joint pain/swelling, areas of localized tenderness and morning stiffness. The final BASDAI score was an average of answers to 6 questions, with an overall possible score range of 0 to 10 cm with higher score represented more severe ankylosing spondylitis disease activity.

Time frame:
Main Study: Baseline (Day 1), Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
Reported as:
Mean · centimeter
Main Study: Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (For Participants With Presence of Spondylitis at Screening and Baseline BASDAI Score >=4 cm) at Months 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36
centimeterTofacitinib
Change at Month 1-2.59 ± 2.324
Change at Month 3-2.41 ± 2.227
Change at Month 6-2.74 ± 2.350
Change at Month 9-2.63 ± 2.175
Change at Month 12-2.65 ± 2.364
Change at Month 15-2.65 ± 2.487
Change at Month 18-2.65 ± 2.652
Change at Month 21-2.47 ± 2.602
Change at Month 24-2.72 ± 2.616
Change at Month 27-2.90 ± 2.640
Change at Month 30-3.27 ± 2.596
Change at Month 33-3.17 ± 2.589
Change at Month 36-3.08 ± 2.459
SecondaryMain Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Component Summary Score at Months 1, 6, 12, 18, 24, 30 and 36

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 8 health domains were aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Norm-based domain scores, PCS and MCS scores were used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represented better physical health status.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Component Summary Score at Months 1, 6, 12, 18, 24, 30 and 36
units on a scaleTofacitinib
Change at Month 16.44 ± 8.285
Change at Month 66.71 ± 8.496
Change at Month 127.23 ± 8.257
Change at Month 187.44 ± 8.729
Change at Month 247.79 ± 9.055
Change at Month 308.06 ± 8.899
Change at Month 367.77 ± 9.074
SecondaryMain Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Mental Component Summary Score at Months 1, 6, 12, 18, 24, 30, and 36

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Mental Component Summary Score at Months 1, 6, 12, 18, 24, 30, and 36
units on a scaleTofacitinib
Change at Month 14.72 ± 10.480
Change at Month 64.98 ± 11.052
Change at Month 125.25 ± 11.072
Change at Month 185.53 ± 11.055
Change at Month 245.79 ± 11.122
Change at Month 305.82 ± 11.726
Change at Month 366.18 ± 11.284
SecondaryMain Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Functioning Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

SF-36v2 was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 10 items of the physical functioning scale represented levels and kinds of limitations between extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence and extent of physical limitations using a 3-level response continuum. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represented better physical functioning.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Functioning Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
units on a scaleTofacitinib
Change at Month 16.06 ± 9.425
Change at Month 66.44 ± 9.834
Change at Month 127.00 ± 9.472
Change at Month 187.31 ± 9.891
Change at Month 247.69 ± 10.280
Change at Month 307.96 ± 10.146
Change at Month 367.80 ± 10.703
SecondaryMain Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Role-Physical Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

SF-36v2 acute was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; \& d) accomplishing less. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represented better role-physical functioning.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Role-Physical Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
units on a scaleTofacitinib
Change at Month 16.19 ± 9.545
Change at Month 66.56 ± 9.650
Change at Month 126.61 ± 9.293
Change at Month 187.07 ± 10.050
Change at Month 247.46 ± 10.094
Change at Month 307.64 ± 10.041
Change at Month 367.40 ± 9.996
SecondaryMain Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Bodily Pain Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represented less bodily pain.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Bodily Pain Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
units on a scaleTofacitinib
Change at Month 18.36 ± 9.797
Change at Month 68.52 ± 10.033
Change at Month 129.29 ± 9.777
Change at Month 189.70 ± 10.271
Change at Month 249.95 ± 10.980
Change at Month 3010.21 ± 10.645
Change at Month 3610.45 ± 10.627
SecondaryMain Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) General Health Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consisted of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher general health domain score represented better general health perceptions.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) General Health Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
units on a scaleTofacitinib
Change at Month 13.89 ± 8.033
Change at Month 64.09 ± 8.640
Change at Month 124.68 ± 8.652
Change at Month 184.76 ± 8.386
Change at Month 244.89 ± 8.608
Change at Month 304.81 ± 8.590
Change at Month 364.36 ± 8.847
SecondaryMain Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Vitality Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher vitality domain score represents better vitality.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Vitality Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
units on a scaleTofacitinib
Change at Month 15.92 ± 10.160
Change at Month 66.03 ± 10.546
Change at Month 126.72 ± 10.367
Change at Month 186.67 ± 10.147
Change at Month 247.10 ± 10.828
Change at Month 307.62 ± 10.808
Change at Month 367.65 ± 10.403
SecondaryMain Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Social Functioning Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assessed health-related effects on quantity and quality of social activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher social functioning domain score represented better social functioning.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Social Functioning Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
units on a scaleTofacitinib
Change at Month 16.08 ± 11.028
Change at Month 66.51 ± 10.923
Change at Month 127.16 ± 10.932
Change at Month 186.76 ± 11.272
Change at Month 247.28 ± 11.487
Change at Month 307.64 ± 11.597
Change at Month 367.83 ± 11.977
SecondaryMain Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2 ) Role-Emotional Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assessed mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher role-emotional domain score represented better role-emotional functioning.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2 ) Role-Emotional Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
units on a scaleTofacitinib
Change at Month 15.40 ± 11.962
Change at Month 65.39 ± 12.445
Change at Month 125.73 ± 12.235
Change at Month 186.71 ± 12.647
Change at Month 246.82 ± 12.154
Change at Month 306.54 ± 12.843
Change at Month 366.95 ± 12.859
SecondaryMain Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2 ) Mental Health Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher mental health domain score represented better mental health functioning.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2 ) Mental Health Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
units on a scaleTofacitinib
Change at Month 14.85 ± 10.306
Change at Month 65.39 ± 10.893
Change at Month 125.56 ± 10.781
Change at Month 185.82 ± 10.730
Change at Month 246.09 ± 11.247
Change at Month 306.18 ± 11.278
Change at Month 366.37 ± 11.199
SecondaryMain Study: Change From Baseline in EuroQol- 5D Health Questionnaire 3-Level (EQ-5D-3L) Mobility Domain at Months 1, 6, 12, 18, 24, 30 and 36

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L mobility domain score were reported in this outcome measure.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30 and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in EuroQol- 5D Health Questionnaire 3-Level (EQ-5D-3L) Mobility Domain at Months 1, 6, 12, 18, 24, 30 and 36
units on a scaleTofacitinib
Change at Month 1-0.24 ± 0.529
Change at Month 6-0.30 ± 0.540
Change at Month 12-0.28 ± 0.511
Change at Month 18-0.30 ± 0.538
Change at Month 24-0.31 ± 0.545
Change at Month 30-0.30 ± 0.526
Change at Month 36-0.32 ± 0.555
SecondaryMain Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Self-Care Domain at Months 1, 6, 12, 18, 24, 30 and 36

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L self-care domain score were reported in this measure.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Self-Care Domain at Months 1, 6, 12, 18, 24, 30 and 36
units on a scaleTofacitinib
Change at Month 1-0.19 ± 0.547
Change at Month 6-0.20 ± 0.530
Change at Month 12-0.19 ± 0.532
Change at Month 18-0.21 ± 0.522
Change at Month 24-0.21 ± 0.534
Change at Month 30-0.23 ± 0.533
Change at Month 36-0.24 ± 0.589
SecondaryMain Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Usual Activities Domain at Months 1, 6, 12, 18, 24, 30 and 36

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L usual activities domain score were reported in this measure.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Usual Activities Domain at Months 1, 6, 12, 18, 24, 30 and 36
units on a scaleTofacitinib
Change at Month 1-0.27 ± 0.588
Change at Month 6-0.30 ± 0.539
Change at Month 12-0.33 ± 0.547
Change at Month 18-0.32 ± 0.579
Change at Month 24-0.36 ± 0.547
Change at Month 30-0.34 ± 0.571
Change at Month 36-0.35 ± 0.594
SecondaryMain Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Pain/Discomfort Domain at Months 1, 6, 12, 18, 24, 30 and 36

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L pain/discomfort domain score were reported in this measure.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Pain/Discomfort Domain at Months 1, 6, 12, 18, 24, 30 and 36
units on a scaleTofacitinib
Change at Month 1-0.31 ± 0.557
Change at Month 6-0.32 ± 0.570
Change at Month 12-0.36 ± 0.568
Change at Month 18-0.40 ± 0.584
Change at Month 24-0.41 ± 0.602
Change at Month 30-0.41 ± 0.601
Change at Month 36-0.40 ± 0.613
SecondaryMain Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Anxiety/Depression Domain at Months 1, 6, 12, 18, 24, 30 and 36

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The status of each dimension had 3 possible responses (1 =no problem, 2 =some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L anxiety/depression domain score were reported in this outcome measure.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Anxiety/Depression Domain at Months 1, 6, 12, 18, 24, 30 and 36
units on a scaleTofacitinib
Change at Month 1-0.23 ± 0.600
Change at Month 6-0.26 ± 0.623
Change at Month 12-0.25 ± 0.594
Change at Month 18-0.26 ± 0.604
Change at Month 24-0.29 ± 0.605
Change at Month 30-0.31 ± 0.608
Change at Month 36-0.29 ± 0.651
SecondaryMain Study: Change From Baseline in EuroQol - Visual Analog Scale (EQ-VAS) Your Own Health State Today Domain at Months 1, 6, 12, 18, 24, 30 and 36

The EQ VAS recorded the participant's self-rated health on a vertical VAS as standard vertical 0 (worst imaginable health state) to 100 mm (best imaginable health state) (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher score indicated a better health state.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · millimeter
Main Study: Change From Baseline in EuroQol - Visual Analog Scale (EQ-VAS) Your Own Health State Today Domain at Months 1, 6, 12, 18, 24, 30 and 36
millimeterTofacitinib
Change at Month 114.12 ± 24.928
Change at Month 615.71 ± 25.871
Change at Month 1216.00 ± 24.896
Change at Month 1816.68 ± 24.746
Change at Month 2417.43 ± 25.226
Change at Month 3017.87 ± 25.363
Change at Month 3618.07 ± 25.185
SecondaryMain Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Months 1, 6, 12, 18, 24, 30 and 36

FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52):calculated by summing 13 items,higher score indicated lower level of fatigue, better participant status. All responses were added with equal weight to get total score.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Months 1, 6, 12, 18, 24, 30 and 36
units on a scaleTofacitinib
Change at Month 17.0 ± 9.78
Change at Month 67.7 ± 10.13
Change at Month 127.8 ± 9.70
Change at Month 188.1 ± 10.06
Change at Month 248.3 ± 10.61
Change at Month 308.7 ± 10.93
Change at Month 369.1 ± 11.05
SecondaryMain Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Experience Domain Score at Months 1, 6, 12, 18, 24, 30 and 36

FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Experience Domain Score at Months 1, 6, 12, 18, 24, 30 and 36
units on a scaleTofacitinib
Change at Month 13.1 ± 4.47
Change at Month 63.4 ± 4.61
Change at Month 123.5 ± 4.48
Change at Month 183.6 ± 4.63
Change at Month 243.7 ± 4.93
Change at Month 303.9 ± 5.02
Change at Month 364.0 ± 4.90
SecondaryMain Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Impact Domain Score at Months 1, 6, 12, 18, 24, 30, and 36

FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.

Time frame:
Main Study: Baseline (Day 1), Months 1, 6, 12, 18, 24, 30, and 36
Reported as:
Mean · units on a scale
Main Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Impact Domain Score at Months 1, 6, 12, 18, 24, 30, and 36
units on a scaleTofacitinib
Change at Month 13.9 ± 5.98
Change at Month 64.2 ± 6.19
Change at Month 124.4 ± 5.88
Change at Month 184.5 ± 6.05
Change at Month 244.6 ± 6.34
Change at Month 304.8 ± 6.46
Change at Month 365.0 ± 6.77
SecondarySub-study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Months 1, 3, 9 and 12

HAQ-DI assessed the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming, arising, eating, walking, reach, grip, hygiene, and other activities. There were total of 2-3 items distributed in each of these 8 domains. Each item was scored for level of difficulty on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain score and divided by the number of domains answered. Total possible HAQ-DI score range 0 (least difficulty) and 3 (extreme difficulty), where higher score indicated more difficulty while performing daily living activities.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Months 1, 3, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.0164 ± 0.024380.0322 ± 0.02411
Change at Month 30.0057 ± 0.025120.0381 ± 0.02474
Change at Month 90.0720 ± 0.031950.0663 ± 0.03125
Change at Month 120.0467 ± 0.029980.0563 ± 0.02941
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0486 · 95% CI -0.0192 to 0.1163
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0325 · 95% CI -0.0372 to 0.1021
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.0058 · 95% CI -0.0941 to 0.0825
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0096 · 95% CI -0.0734 to 0.0927
SecondarySub-study: Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Months 1, 3, 9 and 12

PASDAS was composite PsA disease activity score that included following components: Physician and patient global assessment of disease activity (assessed on a 0-100 VAS) in mm, swollen (66 joints) and tender joint counts (68 joints), Leeds enthesitis index (enthesitis assessed at 6 sites; total score of 0-6), tender dactylitic digit score (scored on a scale of 0-3, where 0= no tenderness and 3= extreme tenderness), SF-36 physical component summary (norm-based domain score were used in analyses; with a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity) and CRP in mg/L. PASDAS was composite score and was a weighted index with score range of 0 to 10, where higher score indicated more severe disease.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Months 1, 3, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 10.000 ± 0.07010.032 ± 0.0696
Change at Month 30.188 ± 0.08690.165 ± 0.0868
Change at Month 90.158 ± 0.09340.371 ± 0.0912
Change at Month 120.194 ± 0.08980.133 ± 0.0882
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.032 · 95% CI -0.163 to 0.227
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.024 · 95% CI -0.266 to 0.219
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.213 · 95% CI -0.045 to 0.470
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.061 · 95% CI -0.309 to 0.188
SecondarySub-study: Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC) at Months 1, 3, 6, 9 and 12

PsARC was comprised of 4 clinical improvement criteria: \>=20% improvement in PhyGA (VAS), \>=20% improvement in PtGA; and \>= 30% reduction in the number of tender joints; and \>=30% reduction in the number of swollen joints. PtGA: participant assessed health on VAS, 0 mm (very well) to 100 mm (worst health condition), higher score = worse condition. PhyGA: physician judged participants' pain on VAS, 0 (no pain) to 100 mm (extreme pain), higher score = more pain. To achieve a clinical response, the participant must improve in 2 of the 4 PsARC criteria, 1 of which has to be the number of tender or swollen joints and none of the 4 score could worsen.

Time frame:
Months 1, 3, 6, 9 and 12
Reported as:
Number · percentage of participants
Sub-study: Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC) at Months 1, 3, 6, 9 and 12
percentage of participantsTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Month 112.3612.22
Month 311.246.67
Month 612.366.67
Month 912.3610.00
Month 1213.483.33
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: -0.14 · 95% CI -9.76 to 9.48
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: -4.57 · 95% CI -12.91 to 3.77
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: -5.69 · 95% CI -14.26 to 2.87
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: -2.36 · 95% CI -11.59 to 6.87
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: -10.15 · 95% CI -18.16 to -2.14
SecondarySub-study: Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Score (For Participants With Baseline PGA-PsO Score >0 ) at Months 1, 3, 6, 9 and 12

The PGA-PsO is a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0-4). Higher score indicated higher disease severity. Severity score for each erythema, induration and scaling were summed and averaged after which the total average was rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0= clear, except for any residual discoloration, 1= almost clear, 2= mild, 3= moderate, 4= severe).

Time frame:
Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Score (For Participants With Baseline PGA-PsO Score >0 ) at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.1 ± 0.100.2 ± 0.11
Change at Month 3-0.1 ± 0.120.1 ± 0.14
Change at Month 6-0.1 ± 0.110.2 ± 0.12
Change at Month 9-0.3 ± 0.130.2 ± 0.13
Change at Month 120.0 ± 0.150.3 ± 0.15
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.2 · 95% CI -0.1 to 0.5
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.2 · 95% CI -0.1 to 0.6
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.3 · 95% CI 0.0 to 0.6
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.5 · 95% CI 0.1 to 0.8
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.3 · 95% CI -0.1 to 0.7
SecondarySub-study: Percent Change From Baseline in Body Surface Area (BSA) (For Participants With BSA >0%) Psoriasis at Months 1, 3, 6, 9 and 12

Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage (Head and neck = 10 handprints \[1 handprint =10%\], upper extremities = 20 handprints \[1 handprint =5%\], Trunk (including axillae and groin) = 30 handprints \[1 handprint =3.33%\], lower extremities (including buttocks) = 40 handprints \[1 handprint =2.5%\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · percent change
Sub-study: Percent Change From Baseline in Body Surface Area (BSA) (For Participants With BSA >0%) Psoriasis at Months 1, 3, 6, 9 and 12
percent changeTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
At Month 128.47 ± 13.4979.04 ± 13.972
At Month 343.58 ± 18.67913.47 ± 19.348
At Month 641.51 ± 20.74517.19 ± 21.157
At Month 935.36 ± 17.30923.72 ± 17.691
At Month 1234.74 ± 19.90941.75 ± 20.333
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -19.43 · 95% CI -58.06 to 19.21
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -30.11 · 95% CI -83.58 to 23.37
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -24.33 · 95% CI -83.35 to 34.69
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -11.64 · 95% CI -60.87 to 37.58
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 7.02 · 95% CI -49.73 to 63.77
SecondarySub-study: Change From Baseline in Dactylitis Severity Score (DSS) (For Participants With Baseline DSS >0) at Months 1, 3, 6, 9 and 12

Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis score for a participant was 0-60. Higher score indicated greater degree of tenderness.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Mean · units on a scale
Sub-study: Change From Baseline in Dactylitis Severity Score (DSS) (For Participants With Baseline DSS >0) at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.4 ± 0.790.0 ± NA
Change at Month 3-0.3 ± 0.52-1.0 ± NA
Change at Month 6-0.3 ± 0.52-1.0 ± NA
Change at Month 9-0.3 ± 0.52-1.0 ± NA
Change at Month 12-0.3 ± 0.52-1.0 ± NA
SecondarySub-study: Percentage of Participants With Absence of Dactylitis (For Participants With Baseline DSS >0) at Months 1, 3, 6, 9 and 12

Dactylitis was characterized by swelling of the entire finger or toe. The DSS was a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis was scored on a scale of 0-3, where 0 =no tenderness and 3 =extreme tenderness in each digit of the hands and feet. The range of total dactylitis score for a participant was 0-60. Higher score indicated greater degree of tenderness.

Time frame:
Sub-study: Months 1, 3, 6, 9 and 12
Reported as:
Number · percentage of participants
Sub-study: Percentage of Participants With Absence of Dactylitis (For Participants With Baseline DSS >0) at Months 1, 3, 6, 9 and 12
percentage of participantsTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Month 114.290.0
Month 314.290.0
Month 614.290.0
Month 914.290.0
Month 1214.290.0
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 6.25 · 95% CI -59.58 to 72.08
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 6.25 · 95% CI -59.58 to 72.08
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 6.25 · 95% CI -59.58 to 72.08
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 6.25 · 95% CI -59.58 to 72.08
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 6.25 · 95% CI -59.58 to 72.08
SecondarySub-study: Change From Baseline in Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI >0) at Months 1, 3, 6, 9 and 12

Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI >0) at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.2 ± 0.25-0.4 ± 0.24
Change at Month 3-0.3 ± 0.23-0.5 ± 0.23
Change at Month 6-0.5 ± 0.29-0.7 ± 0.28
Change at Month 9-0.3 ± 0.290.0 ± 0.28
Change at Month 12-0.5 ± 0.28-0.3 ± 0.27
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.2 · 95% CI -0.9 to 0.5
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.2 · 95% CI -0.9 to 0.5
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.2 · 95% CI -1.1 to 0.6
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.2 · 95% CI -0.6 to 1.1
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.2 · 95% CI -0.6 to 1.0
SecondarySub-study: Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI =0) at Months 1, 3, 6, 9 and 12

Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.

Time frame:
Sub-study: Months 1, 3, 6, 9 and 12
Reported as:
Mean · units on a scale
Sub-study: Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI =0) at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Month 10.2 ± 0.640.1 ± 0.58
Month 30.2 ± 0.560.0 ± 0.24
Month 60.2 ± 0.760.2 ± 0.82
Month 90.1 ± 0.240.1 ± 0.46
Month 120.2 ± 0.670.1 ± 0.49
SecondarySub-study: Percentage of Participants With Absence of Enthesitis Assessed Using Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI >0) at Months 1, 3, 6, 9 and 12

Enthesitis was inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assessed enthesitis in 6 sites including (right and left): lateral epicondyle humerus, medial femoral condyle and achilles tendon insertion. Tenderness is recorded as either present (score 1) or absent (score 0) for each of the 6 sites for a total score of 0-6. Higher score indicated a greater number of sites that are affected by enthesitis.

Time frame:
Sub-study: Months 1, 3, 6, 9 and 12
Reported as:
Number · percentage of participants
Sub-study: Percentage of Participants With Absence of Enthesitis Assessed Using Leeds Enthesitis Index (LEI) (For Participants With Baseline LEI >0) at Months 1, 3, 6, 9 and 12
percentage of participantsTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Month 113.3325.00
Month 313.3343.75
Month 626.6756.25
Month 913.3337.50
Month 1226.6743.75
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 11.67 · 95% CI -15.65 to 38.98
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 30.42 · 95% CI 0.64 to 60.20
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 29.58 · 95% CI -3.46 to 62.62
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 24.17 · 95% CI -5.14 to 53.47
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 17.08 · 95% CI -15.96 to 50.12
SecondarySub-study: Percentage of Participants With Minimal Disease Activity (MDA) at Months 1, 3, 6, 9 and 12

A psoriatic arthritis participant was considered with minimal disease activity if participant had \>= 5 of 7 criteria: 1) tender/painful joint count less than or equals to (\<=) 1; (2) swollen joint count \<=1; (3) BSA \<=3%; (4) Patient Assessment of Arthritis Pain (VAS) \<=15 mm; (5) PtGA (VAS) \<=20 mm; (6) HAQ-DI score \<=0.5; (7) tender entheseal points (using LEI) \<=1.

Time frame:
Sub-study: Months 1, 3, 6, 9 and 12
Reported as:
Number · percentage of participants
Sub-study: Percentage of Participants With Minimal Disease Activity (MDA) at Months 1, 3, 6, 9 and 12
percentage of participantsTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Month 150.5655.56
Month 350.5654.44
Month 646.0748.89
Month 942.7046.67
Month 1241.5744.44
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 4.99 · 95% CI -9.61 to 19.60
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 3.88 · 95% CI -10.74 to 18.50
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 2.82 · 95% CI -11.80 to 17.45
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 3.97 · 95% CI -10.58 to 18.52
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Difference in percentage of participants: 2.87 · 95% CI -11.63 to 17.37
SecondarySub-study: Change From Baseline in Tender/Painful Joint Count at Months 1, 3, 6, 9 and 12

68 joints were assessed to determine joints that are considered tender or painful. Response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Done/Not Applicable (to be used for artificial or missing joints). The 68 joints assessed were: 1) Upper Body: temporomandibular, sternoclavicular, acromioclavicular. 2) Upper Extremity: shoulder, elbow, wrist (includes radiocarpal, carpal and carpometacarpal considered as one unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), distal interphalangeals (DIP II, III, IV, V). 3) Lower Extremity: hip, knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · tender/painful joints
Sub-study: Change From Baseline in Tender/Painful Joint Count at Months 1, 3, 6, 9 and 12
tender/painful jointsTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 10.7 ± 0.370.3 ± 0.37
Change at Month 31.3 ± 0.440.9 ± 0.44
Change at Month 60.5 ± 0.370.5 ± 0.37
Change at Month 90.4 ± 0.330.4 ± 0.32
Change at Month 120.3 ± 0.320.5 ± 0.32
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.4 · 95% CI -1.5 to 0.6
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.4 · 95% CI -1.6 to 0.8
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -1.0 to 1.0
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.9 to 0.9
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.2 · 95% CI -0.7 to 1.1
SecondarySub-study: Change From Baseline in Swollen Joint Count at Months 1, 3, 6, 9 and 12

Joints were assessed for swelling using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). Sixty-six (66) joints were assessed for swelling. The 66 joints assessed were: 1) Upper Body: temporomandibular, sternoclavicular, acromioclavicular. 2) Upper Extremity: shoulder, elbow, wrist (includes radiocarpal, carpal and carpometacarpal considered as one unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal (IP), proximal interphalangeals (PIP II, III, IV, V), distal interphalangeals (DIP II, III, IV, V). 3) Lower Extremity: knee, ankle, tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe IP, proximal and distal interphalangeals combined (PIP II, III, IV, V).

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · swollen joints
Sub-study: Change From Baseline in Swollen Joint Count at Months 1, 3, 6, 9 and 12
swollen jointsTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.1 ± 0.140.0 ± 0.14
Change at Month 30.3 ± 0.210.3 ± 0.21
Change at Month 60.1 ± 0.160.1 ± 0.15
Change at Month 90.0 ± 0.170.2 ± 0.17
Change at Month 120.1 ± 0.140.0 ± 0.14
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.1 · 95% CI -0.3 to 0.5
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.6 to 0.6
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.4 to 0.5
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.2 · 95% CI -0.3 to 0.7
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.1 · 95% CI -0.5 to 0.3
SecondarySub-study: Change From Baseline in Physician's Global Assessment of Arthritis (PhyGA) at Months 1, 3, 6, 9 and 12

The investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and independent of the PtGA and Patient Assessment of Arthritis Pain. The investigator's response was recorded using a 100 mm VAS where 0 =PSA not active at all and 100 =PSA extremely active. Higher score indicated more PSA.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · millimeter
Sub-study: Change From Baseline in Physician's Global Assessment of Arthritis (PhyGA) at Months 1, 3, 6, 9 and 12
millimeterTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.42 ± 0.992-0.17 ± 0.981
Change at Month 31.98 ± 1.2252.76 ± 1.216
Change at Month 61.18 ± 0.9831.65 ± 0.966
Change at Month 91.18 ± 1.3163.35 ± 1.287
Change at Month 120.86 ± 1.1270.75 ± 1.111
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.26 · 95% CI -2.51 to 3.02
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.77 · 95% CI -2.64 to 4.18
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.47 · 95% CI -2.26 to 3.20
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 2.18 · 95% CI -1.46 to 5.81
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.12 · 95% CI -3.25 to 3.01
SecondarySub-study: Change From Baseline in Patient's Global Assessment of Arthritis (PtGA) at Months 1, 3, 6, 9 and 12

Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participant's response were recorded using a 0 - 100 mm VAS where 0 =not affected at all and 100 =extremely affected. Higher score indicated worse condition due to PSA.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · millimeter
Sub-study: Change From Baseline in Patient's Global Assessment of Arthritis (PtGA) at Months 1, 3, 6, 9 and 12
millimeterTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 11.35 ± 1.277-0.68 ± 1.264
Change at Month 32.11 ± 1.5371.68 ± 1.516
Change at Month 63.17 ± 1.7254.45 ± 1.690
Change at Month 92.63 ± 1.6913.27 ± 1.655
Change at Month 122.77 ± 1.6292.65 ± 1.602
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -2.03 · 95% CI -5.58 to 1.52
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.43 · 95% CI -4.69 to 3.84
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 1.29 · 95% CI -3.48 to 6.06
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.64 · 95% CI -4.03 to 5.32
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.13 · 95% CI -4.64 to 4.38
SecondarySub-study: Change From Baseline in Patient's Assessment of Arthritis Pain at Months 1, 3, 6, 9 and 12

Participants assessed the severity of their arthritis pain using a 100 mm VAS by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. Higher score indicated more severe pain.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · millimeter
Sub-study: Change From Baseline in Patient's Assessment of Arthritis Pain at Months 1, 3, 6, 9 and 12
millimeterTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.05 ± 1.383-1.16 ± 1.370
Change at Month 31.59 ± 1.3940.36 ± 1.380
Change at Month 63.12 ± 1.7094.07 ± 1.674
Change at Month 92.44 ± 1.7804.45 ± 1.741
Change at Month 122.69 ± 1.6923.35 ± 1.664
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -1.11 · 95% CI -4.96 to 2.74
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -1.23 · 95% CI -5.11 to 2.65
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.95 · 95% CI -3.78 to 5.69
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 2.01 · 95% CI -2.92 to 6.93
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.66 · 95% CI -4.03 to 5.35
SecondarySub-study: Change From Baseline in C-Reactive Protein (CRP) at Months 1, 3, 6, 9 and 12

The test for CRP was a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · mg/L
Sub-study: Change From Baseline in C-Reactive Protein (CRP) at Months 1, 3, 6, 9 and 12
mg/LTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.1171 ± 0.71654-0.2706 ± 0.70892
Change at Month 3-0.3625 ± 0.48088-0.9285 ± 0.47675
Change at Month 60.5354 ± 0.79954-0.2637 ± 0.78002
Change at Month 9-0.3217 ± 0.59271-0.2591 ± 0.57983
Change at Month 12-0.1005 ± 0.786500.2667 ± 0.77230
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.1535 · 95% CI -2.1444 to 1.8374
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.5660 · 95% CI -1.9054 to 0.7735
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.7991 · 95% CI -3.0053 to 1.4071
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0626 · 95% CI -1.5767 to 1.7018
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.3672 · 95% CI -1.8107 to 2.5450
SecondarySub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Component Summary Score at Months 1, 3, 6, 9 and 12

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represents better physical health status.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Component Summary Score at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.55 ± 0.424-0.22 ± 0.419
Change at Month 3-0.90 ± 0.492-0.57 ± 0.487
Change at Month 6-0.65 ± 0.480-1.42 ± 0.466
Change at Month 9-1.09 ± 0.607-1.85 ± 0.593
Change at Month 12-1.52 ± 0.533-1.00 ± 0.523
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.33 · 95% CI -0.85 to 1.51
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.33 · 95% CI -1.04 to 1.69
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.77 · 95% CI -2.09 to 0.55
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.77 · 95% CI -2.44 to 0.91
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.52 · 95% CI -0.96 to 2.00
SecondarySub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Mental Component Summary Score at Months 1, 3, 6, 9 and 12

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Mental Component Summary Score at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 10.35 ± 0.630-0.11 ± 0.622
Change at Month 30.09 ± 0.642-0.77 ± 0.634
Change at Month 6-0.23 ± 0.733-0.89 ± 0.713
Change at Month 9-0.71 ± 0.7490.06 ± 0.731
Change at Month 12-0.38 ± 0.694-0.47 ± 0.681
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.47 · 95% CI -2.22 to 1.29
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.86 · 95% CI -2.65 to 0.92
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.66 · 95% CI -2.68 to 1.36
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.76 · 95% CI -1.31 to 2.83
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.09 · 95% CI -2.01 to 1.84
SecondarySub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Functioning Domain Score at Months 1, 3, 6, 9 and 12

SF-36v2 was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 10 items of the physical functioning scale represented levels and kinds of limitations between extremes of physical activities, including lifting \& carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence \& extent of physical limitations using a 3-level response continuum. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represented better physical functioning.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Physical Functioning Domain Score at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.37 ± 0.472-0.15 ± 0.467
Change at Month 3-0.50 ± 0.562-0.33 ± 0.556
Change at Month 6-0.27 ± 0.586-0.80 ± 0.571
Change at Month 9-1.43 ± 0.657-1.11 ± 0.643
Change at Month 12-1.01 ± 0.676-1.02 ± 0.664
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.22 · 95% CI -1.09 to 1.53
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.17 · 95% CI -1.39 to 1.73
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.53 · 95% CI -2.15 to 1.08
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.32 · 95% CI -1.49 to 2.13
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.01 · 95% CI -1.89 to 1.86
SecondarySub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Role Physical Domain Score at Months 1, 3, 6, 9 and 12

SF-36v2 acute was a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. The 4-item role-physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; \& d) accomplishing less. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represented better role-physical functioning.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Role Physical Domain Score at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.27 ± 0.5610.22 ± 0.555
Change at Month 3-1.04 ± 0.6260.21 ± 0.619
Change at Month 6-1.57 ± 0.585-0.87 ± 0.569
Change at Month 9-0.64 ± 0.638-0.44 ± 0.624
Change at Month 12-1.85 ± 0.646-0.12 ± 0.635
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.48 · 95% CI -1.08 to 2.05
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 1.25 · 95% CI -0.49 to 2.99
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.70 · 95% CI -0.91 to 2.31
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.20 · 95% CI -1.57 to 1.96
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 1.73 · 95% CI -0.06 to 3.52
SecondarySub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Bodily Pain Domain Score at Months 1, 3, 6, 9 and 12

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represented less bodily pain.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Bodily Pain Domain Score at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.77 ± 0.617-0.06 ± 0.609
Change at Month 3-1.59 ± 0.661-1.24 ± 0.652
Change at Month 6-0.61 ± 0.686-2.42 ± 0.669
Change at Month 9-1.29 ± 0.808-3.05 ± 0.790
Change at Month 12-1.69 ± 0.719-1.99 ± 0.706
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.71 · 95% CI -1.01 to 2.42
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.34 · 95% CI -1.49 to 2.18
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -1.81 · 95% CI -3.70 to 0.09
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -1.76 · 95% CI -3.99 to 0.48
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.30 · 95% CI -2.30 to 1.69
SecondarySub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) General Health Domain Score at Months 1, 3, 6, 9 and 12

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The general health scale consisted of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher general health domain score represented better general health perceptions.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) General Health Domain Score at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 10.20 ± 0.492-0.48 ± 0.487
Change at Month 30.34 ± 0.516-0.79 ± 0.511
Change at Month 60.24 ± 0.493-0.57 ± 0.481
Change at Month 9-0.48 ± 0.562-0.46 ± 0.551
Change at Month 12-0.32 ± 0.539-0.29 ± 0.530
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.68 · 95% CI -2.05 to 0.69
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -1.13 · 95% CI -2.57 to 0.31
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.81 · 95% CI -2.17 to 0.56
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.01 · 95% CI -1.54 to 1.57
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.04 · 95% CI -1.46 to 1.53
SecondarySub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Vitality Domain Score at Months 1, 3, 6, 9 and 12

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher vitality domain score represented better vitality.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Vitality Domain Score at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.04 ± 0.614-0.39 ± 0.607
Change at Month 3-0.26 ± 0.593-1.12 ± 0.586
Change at Month 60.01 ± 0.705-1.70 ± 0.687
Change at Month 9-0.80 ± 0.645-1.27 ± 0.632
Change at Month 12-1.04 ± 0.640-0.09 ± 0.629
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.36 · 95% CI -2.06 to 1.35
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.86 · 95% CI -2.51 to 0.79
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -1.71 · 95% CI -3.66 to 0.23
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.47 · 95% CI -2.25 to 1.32
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.95 · 95% CI -0.82 to 2.73
SecondarySub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Social Functioning Domain Score at Months 1, 3, 6, 9 and 12

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 2-item social functioning scale assessed health-related effects on quantity and quality of social activities. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher social functioning domain score represented better social functioning.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Social Functioning Domain Score at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.99 ± 0.734-0.22 ± 0.726
Change at Month 3-0.80 ± 0.750-1.18 ± 0.740
Change at Month 6-1.16 ± 0.776-1.74 ± 0.757
Change at Month 9-1.50 ± 0.753-1.22 ± 0.737
Change at Month 12-1.81 ± 0.758-1.28 ± 0.746
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.78 · 95% CI -1.27 to 2.82
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.38 · 95% CI -2.46 to 1.71
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.57 · 95% CI -2.72 to 1.57
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.28 · 95% CI -1.81 to 2.36
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.53 · 95% CI -1.58 to 2.63
SecondarySub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Role Emotional Domain Score at Months 1, 3, 6, 9 and 12

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 3-item role-emotional scale assessed mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher role-emotional domain score represented better role-emotional functioning.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub-study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Role Emotional Domain Score at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 11.14 ± 0.716-0.53 ± 0.707
Change at Month 30.24 ± 0.807-0.38 ± 0.797
Change at Month 6-0.72 ± 0.788-0.82 ± 0.769
Change at Month 9-0.78 ± 0.803-0.06 ± 0.782
Change at Month 12-0.33 ± 0.835-1.11 ± 0.820
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -1.67 · 95% CI -3.67 to 0.32
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.61 · 95% CI -2.86 to 1.63
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.09 · 95% CI -2.27 to 2.09
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.73 · 95% CI -1.49 to 2.95
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.79 · 95% CI -3.10 to 1.53
SecondarySub Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Mental Health Domain Score at Months 1, 3, 6, 9 and 12

The SF-36v2 acute was a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. Norm-based domain scores were used in the analyses; each of which had a population mean of 50 with a SD of 10 points, and ranged from minus infinity to plus infinity. A higher mental health domain score represented better mental health functioning.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub Study: Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Mental Health Domain Score at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.30 ± 0.6760.63 ± 0.669
Change at Month 3-0.42 ± 0.661-0.31 ± 0.653
Change at Month 6-0.01 ± 0.780-0.26 ± 0.762
Change at Month 9-0.72 ± 0.7240.35 ± 0.710
Change at Month 12-0.37 ± 0.7230.01 ± 0.711
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.93 · 95% CI -0.95 to 2.81
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.11 · 95% CI -1.72 to 1.95
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.25 · 95% CI -2.40 to 1.90
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 1.07 · 95% CI -0.93 to 3.07
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.38 · 95% CI -1.62 to 2.38
SecondarySub Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Months 1, 3, 6, 9 and 12

FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52):calculated by summing 13 items,higher score indicated lower level of fatigue, better participant status. All responses were added with equal weight to get total score.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-1.9 ± 0.61-1.1 ± 0.61
Change at Month 3-1.8 ± 0.59-1.3 ± 0.58
Change at Month 6-1.3 ± 0.61-2.0 ± 0.60
Change at Month 9-2.1 ± 0.65-1.0 ± 0.64
Change at Month 12-1.4 ± 0.66-0.7 ± 0.64
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.8 · 95% CI -0.9 to 2.5
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.5 · 95% CI -1.1 to 2.2
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.7 · 95% CI -2.4 to 1.0
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 1.1 · 95% CI -0.8 to 2.9
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.8 · 95% CI -1.1 to 2.6
SecondarySub Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Experience Domain Score at Months 1, 3, 6, 9 and 12

FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Experience Domain Score at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-0.9 ± 0.29-0.5 ± 0.29
Change at Month 3-0.8 ± 0.31-0.9 ± 0.30
Change at Month 6-0.5 ± 0.29-1.3 ± 0.28
Change at Month 9-0.7 ± 0.31-0.8 ± 0.30
Change at Month 12-0.5 ± 0.31-0.5 ± 0.31
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.4 · 95% CI -0.4 to 1.2
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.1 · 95% CI -1.0 to 0.7
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.7 · 95% CI -1.6 to 0.1
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.9 to 0.8
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.9 to 0.8
SecondarySub Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Impact Domain Score at Months 1, 3, 6, 9 and 12

FACIT-F:13-item questionnaire answered by participants,with each item scaled from 0(not at all) to 4(very much). 3 endpoints were derived:1)change in FACIT-F experience domain(score 0-20, higher score indicate less fatigue experience),calculated by summing 5 items(felt fatigued,felt weak all over,felt listless \["washed out"\],felt tired,had energy; 2)change in FACIT-F impact domain(score 0-32,higher score indicate less fatigue impact on daily functioning),calculated by summing remaining 8 items(had trouble starting things as tired,had trouble finishing things as tired,was able to do usual activities,needed to sleep during day,too tired to eat,needed help doing my usual activities,frustrated by being too tired to do things wanted to do,had to limit my social activity because tired); 3)change in FACIT-F total score(0-52,higher score indicated lower level of fatigue, better participant status):calculated by summing 13 items, all responses were added with equal weight to get total score.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub Study: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Impact Domain Score at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 1-1.1 ± 0.39-0.6 ± 0.39
Change at Month 3-1.1 ± 0.35-0.4 ± 0.35
Change at Month 6-0.8 ± 0.41-0.7 ± 0.40
Change at Month 9-1.4 ± 0.42-0.2 ± 0.41
Change at Month 12-0.9 ± 0.40-0.1 ± 0.40
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.5 · 95% CI -0.6 to 1.6
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.7 · 95% CI -0.3 to 1.7
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.1 · 95% CI -1.0 to 1.2
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 1.2 · 95% CI 0.0 to 2.3
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.8 · 95% CI -0.3 to 1.9
SecondarySub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Mobility Domain at Months 1, 3, 6, 9 and 12

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L mobility domain score were reported in this measure.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Mobility Domain at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 10.0 ± 0.040.0 ± 0.04
Change at Month 30.0 ± 0.040.0 ± 0.04
Change at Month 60.0 ± 0.040.1 ± 0.04
Change at Month 90.0 ± 0.040.1 ± 0.04
Change at Month 120.0 ± 0.040.1 ± 0.04
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.1 · 95% CI -0.1 to 0.2
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.1 to 0.2
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.1 · 95% CI -0.1 to 0.2
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.1 · 95% CI -0.1 to 0.2
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.1 · 95% CI 0.0 to 0.2
SecondarySub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Self-Care Domain at Months 1, 3, 6, 9 and 12

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L self-care domain score were reported in this measure.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Self-Care Domain at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 10.0 ± 0.030.0 ± 0.03
Change at Month 30.0 ± 0.030.0 ± 0.03
Change at Month 60.0 ± 0.040.0 ± 0.03
Change at Month 90.0 ± 0.040.0 ± 0.04
Change at Month 120.0 ± 0.040.1 ± 0.04
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI 0.0 to 0.1
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.1 · 95% CI 0.0 to 0.2
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.1 · 95% CI 0.0 to 0.2
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.1 to 0.1
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.1 to 0.1
SecondarySub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Usual Activities Domain at Months 1, 3, 6, 9 and 12

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L usual activities domain score were reported in this measure.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Usual Activities Domain at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 10.0 ± 0.040.0 ± 0.04
Change at Month 30.0 ± 0.040.0 ± 0.04
Change at Month 60.0 ± 0.040.1 ± 0.04
Change at Month 90.1 ± 0.040.1 ± 0.04
Change at Month 120.0 ± 0.040.0 ± 0.04
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.1 to 0.1
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.1 · 95% CI -0.1 to 0.2
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.1 · 95% CI 0.0 to 0.2
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.1 to 0.1
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.1 · 95% CI -0.1 to 0.2
SecondarySub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Pain/Discomfort Domain

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L pain/discomfort domain score were reported in this measure.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Pain/Discomfort Domain
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 10.1 ± 0.040.0 ± 0.04
Change at Month 30.1 ± 0.040.1 ± 0.04
Change at Month 60.1 ± 0.040.1 ± 0.04
Change at Month 90.1 ± 0.050.1 ± 0.05
Change at Month 120.1 ± 0.050.2 ± 0.05
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.1 to 0.1
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.1 · 95% CI -0.1 to 0.2
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.1 to 0.1
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.1 to 0.2
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.1 · 95% CI -0.1 to 0.2
SecondarySub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Anxiety/Depression Domain at Months 1, 3, 6, 9 and 12

EQ-5D-3L, a health profile questionnaire was used to assess quality of life along 5 dimensions i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. The status of each dimension had 3 possible responses (1 =no problem, 2= some problem 3 =severe problems) in the relevant health dimension. Higher score indicated a worsening health condition. Data for change from baseline in EQ-5D-3L anxiety/depression domain score were reported in this measure.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Sub Study: Change From Baseline in EuroQol-5D Health Questionnaire 3-Level (EQ-5D-3L) Anxiety/Depression Domain at Months 1, 3, 6, 9 and 12
units on a scaleTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 10.1 ± 0.040.0 ± 0.04
Change at Month 30.0 ± 0.050.0 ± 0.04
Change at Month 60.1 ± 0.050.0 ± 0.05
Change at Month 90.1 ± 0.050.0 ± 0.05
Change at Month 120.1 ± 0.050.0 ± 0.05
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.2 to 0.1
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: 0.0 · 95% CI -0.2 to 0.1
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.1 · 95% CI -0.2 to 0.1
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.1 · 95% CI -0.3 to 0.0
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -0.1 · 95% CI -0.2 to 0.0
SecondarySub Study: Change From Baseline in EuroQol - Visual Analog Scale (EQ-VAS) Your Own Health State Today Domain at Months 1, 3, 6, 9 and 12

The EQ VAS recorded the participant's self-rated health on a vertical VAS as standard verticle 0 (worst imaginable health state) to 100 mm (best imaginable health state) (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher score indicated a better health state.

Time frame:
Sub-study: Baseline (Day 1), Months 1, 3, 6, 9 and 12
Reported as:
Least squares mean · millimeter
Sub Study: Change From Baseline in EuroQol - Visual Analog Scale (EQ-VAS) Your Own Health State Today Domain at Months 1, 3, 6, 9 and 12
millimeterTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Change at Month 12.0 ± 1.19-0.9 ± 1.16
Change at Month 30.5 ± 1.54-1.1 ± 1.52
Change at Month 64.4 ± 1.41-1.9 ± 1.38
Change at Month 92.5 ± 1.59-0.4 ± 1.56
Change at Month 123.0 ± 1.82-1.9 ± 1.78
Statistical analysis
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -2.9 · 95% CI -6.2 to 0.4
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -1.5 · 95% CI -5.8 to 2.7
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -6.3 · 95% CI -10.2 to -2.4
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -2.8 · 95% CI -7.3 to 1.6
  • Tofacitinib 5 mg BID + Methotrexate (MTX) vs Tofacitinib 5 mg BID + Placebo · Ls mean difference: -4.9 · 95% CI -9.9 to 0.2

Adverse events

Collected over Baseline (Day 1) up to last dose of main study (maximum up to 36 months) if not enrolled into sub-study or from baseline up to last dose of sub-study (maximum up to 48 months) if enrolled into sub-study. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Tofacitinib6/686 (0.9%)115/686 (16.8%)457/686 (66.6%)
Tofacitinib 5 mg BID + Methotrexate (MTX)0/89 (0%)3/89 (3.4%)25/89 (28.1%)
Tofacitinib 5 mg BID + Placebo0/90 (0%)4/90 (4.4%)24/90 (26.7%)
Most frequent serious events
Showing 10 of 144
Most frequent serious events
EventAll TofacitinibTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
HaematemesisGastrointestinal disorders1/6861/890/90
MelaenaGastrointestinal disorders1/6861/890/90
AppendicitisInfections and infestations1/6861/890/90
Pneumonia herpes viralInfections and infestations1/6861/890/90
Psoriatic arthropathyMusculoskeletal and connective tissue disorders1/6860/891/90
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/6860/891/90
ParaesthesiaNervous system disorders1/6860/891/90
Forearm fractureInjury, poisoning and procedural complications1/6860/891/90
OsteoarthritisMusculoskeletal and connective tissue disorders7/6860/890/90
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders4/6860/890/90
Most frequent other events
Showing 10 of 36
Most frequent other events
EventAll TofacitinibTofacitinib 5 mg BID + Methotrexate (MTX)Tofacitinib 5 mg BID + Placebo
Upper respiratory tract infectionInfections and infestations124/6866/894/90
NasopharyngitisInfections and infestations104/6861/893/90
BronchitisInfections and infestations67/6862/893/90
Urinary tract infectionInfections and infestations66/6863/894/90
HypertensionVascular disorders50/6862/892/90
Psoriatic arthropathyMusculoskeletal and connective tissue disorders44/6863/890/90
PharyngitisInfections and infestations38/6863/893/90
Blood creatine phosphokinase increasedInvestigations36/6860/890/90
Alanine aminotransferase increasedInvestigations34/6860/890/90
SinusitisInfections and infestations33/6860/890/90

Baseline characteristics

Safety analysis set (SAS) included all participants enrolled in this study who were part of a prior qualifying study, and who received at least one dose of open-label study medication in A3921092. Full analysis set (FAS) and the SAS were same in this study.

Age, Continuous
Age, Continuous(years)Tofacitinib: All Participants
Mean48.8 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib: All Participants
Female370
Male316
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tofacitinib: All Participants
American Indian or Alaska Native0
Asian21
Native Hawaiian or Other Pacific Islander0
Black or African American2
White646
More than one race17
Unknown or Not Reported0
08

Study locations

153 sites
  • Rheumatology Associates, PC
    Birmingham, Alabama 35205, United States
  • Rheumatology Associates of North Alabama, PC
    Huntsville, Alabama 35801, United States
  • Arizona Arthritis & Rheumatology Associates, P.C.
    Glendale, Arizona 85306, United States
  • St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
    Fullerton, California 92835, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • San Diego Arthritis Medical Clinic
    San Diego, California 92108, United States
  • Stanford Anatomic Pathology and Clinical Lab
    Stanford, California 94305, United States
  • Stanford Health Care Department of Pharmacy lnvestigational Drug Services
    Stanford, California 94305, United States
  • Stanford University Hospitals and Clinics
    Stanford, California 94305, United States
  • New England Research Associates, LLC
    Bridgeport, Connecticut 06606, United States
  • Rheumatology Associates of Central Florida, PA
    Orlando, Florida 32806, United States
  • Millennium Research
    Ormond Beach, Florida 32174, United States
  • Arthritis Center, Inc.
    Palm Harbour, Florida 34684, United States
  • Guillermo Valenzuela, MD PA dba Integral Rheumatology & Immunology Specialists
    Plantation, Florida 33324, United States
  • Florida Medical Clinic, P.A.
    Zephyrhills, Florida 33542, United States
  • St. Luke's Clinic - Rheumatology
    Boise, Idaho 83702, United States
  • St. Luke's Intermountain Research Center
    Boise, Idaho 83702, United States
  • Bluegrass Community Research, Inc.
    Lexington, Kentucky 40504, United States
  • Klein and Associates, M.D., P.A.
    Hagerstown, Maryland 21740, United States
  • The Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • St. Paul Rheumatology, P.A.
    Eagan, Minnesota 55121, United States
  • Clayton Medical Research
    Saint Louis, Missouri 63117, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Cincinnati Rheumatic Disease Study Group, Inc.
    Cincinnati, Ohio 45242, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • University Hospitals of Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Paramount Medical Research & Consulting, LLC
    Middleburg Heights, Ohio 44130, United States
  • East Penn Rheumatology Associates, PC
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology
    Summerville, South Carolina 29486, United States
  • Arthritis Clinic
    Jackson, Tennessee 38305, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Adriana Pop-Moody MD Clinic PA
    Corpus Christi, Texas 78404, United States
  • Pioneer Research Solutions, Inc.
    Cypress, Texas 77429, United States
  • Investigational Drug Services
    Salt Lake City, Utah 84112, United States
  • University of Utah Hospital & Clinics
    Salt Lake City, Utah 84132, United States
  • University of Utah Hospitals and Clinics - Clinie 2
    Salt Lake City, Utah 84132, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • Seattle Rheumatology Associates
    Seattle, Washington 98122, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Rheumatology Research Unit
    Maroochydore, Queensland 4558, Australia
  • Pacific Private Clinic
    Southport, Queensland 4215, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • St. Vincent's Hospital (Melbourne)
    Fitzroy, Victoria 3065, Australia
  • St. Vincent's Hospital
    Fitzroy, Victoria 3065, Australia
  • Hopital Erasme - Clinique Universitaire de Bruxelles
    Brussels, Brabant Flamand 1070, Belgium
  • Hopital Erasme - Clinique Universitaire de Bruxelles
    Brussels, 1070, Belgium
  • Reumaclinic
    Genk, 3600, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • University Hospital Leuven
    Leuven, 3000, Belgium
  • ZNA Jan Palfijn
    Merksem, 2170, Belgium
  • CMIP- Centro Mineiro de Pesquisa Ltda/CETAL- Centro de Estudos e Tratamento do Aparelho Locomotor
    Juiz de Fora, MG 36010-570, Brazil
  • EDUMED - Educação em Saùde SS Ltda
    Curitiba, PR 80440-080, Brazil
  • Hospital de Clinicas de Porto Alegre (HCPA) / UFRGS
    Porto Alegre, RS 90035-903, Brazil
  • UMHAT "Dr. G. Stranski" EAD, Department of Rheumatology
    Pleven, 5800, Bulgaria
  • Multiprofile Hospital for Active Treatment - Plovdiv AD
    Plovdiv, 4000, Bulgaria
  • Multiprofile hospital for active treatment Kaspela EOOD
    Plovdiv, 4002, Bulgaria
  • Medical Center - "New rehabilitation center" EOOD
    Stara Zagora, 6003, Bulgaria
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • X-Medica, s.r.o.
    Brno, 613 00, Czechia
  • Revmacentrum MUDr. Mostera, s.r.o.
    Brno, 615 00, Czechia
  • Stavovska, s.r.o.
    Brno, 638 00, Czechia
  • Revmatologie s.r.o.
    Brno, 63800, Czechia
  • Vesalion s.r.o.
    Ostrava, 702 00, Czechia
  • Revmatologicky ustav - Lekarna
    Praha 2, 128 50, Czechia
  • Revmatologicky ustav
    Praha 2, 128 50, Czechia
  • Revmatologicka ambulance
    Praha 4, 140 00, Czechia
  • MEDICAL PLUS, s.r.o.
    Uherske Hradiste, 686 01, Czechia
  • Rheumazentrum Prof. Dr. med Gunther Neeck
    Bad Doberan, Mecklenburg-vorp 18209, Germany
  • Charite Universitaetsmedizin Berlin
    Berlin, 10117, Germany
  • Klinische Forschung Berlin-Mitte GmbH
    Berlin, 10117, Germany
  • Rheumapraxis Steglitz
    Berlin, 12161, Germany
  • Schlosspark-Klinik
    Berlin, 14059, Germany
  • CIRI, Centrum fuer innovative Diagnostik und Therapie Rheumatologie und Immunologie (GmbH)
    Frankfurt am Main, 60598, Germany
  • Medizinische Universitaetsklinik Freiburg
    Freiburg, 79106, Germany
  • Universitaetsklinikum Des Saarlandes Und Medizinische Fakultaet Der Universitaet Des Saarlandes
    Homburg, 66421, Germany
  • University Hospital of Cologne
    Koeln, 50937, Germany
  • Elisabeth Klinik Bigge
    Olsberg, 59939, Germany
  • Diagnoscan Magyarország Kft.
    Budapest, 1024, Hungary
  • Budapest Fovaros II. keruleti Onkormanyzat Egeszsegugyi Szolgalata- Rontgen- Ultrahang
    Budapest, 1027, Hungary
  • Revita Reumatologiai Rendelo
    Budapest, 1027, Hungary
  • Qualiclinic Kft.
    Budapest, 1036, Hungary
  • Magyar Honvedseg Egeszsegugyi Kozpont - Kozponti Radiologiai Diagnosztika Osztaly
    Budapest, 1062, Hungary
  • Magyar Honvedseg Egeszsegugyi Kozpont, Reumatologiai Osztaly
    Budapest, 1062, Hungary
  • Csolnoky Ferenc Korhaz, Reumatologiai Osztaly
    Veszprem, 8200, Hungary
  • Csolnoky Ferenc Korhaz
    Veszprem, 8200, Hungary
  • Hospital Angeles Clinica Londres
    Mexico City, D.F 06700, Mexico
  • Grupo Medico Camino S.C.
    Mexico City, Distrito Federal 03310, Mexico
  • Cliditer, S.A. DE C.V.
    Mexico City, Distrito Federal 06700, Mexico
  • Centro Integral en Reumatologia S.A. de C.V.
    Guadalajara, Jalisco 44160, Mexico
  • Centro de Investigacion de Tratamientos Innovadores de Sinaloa, S.C.
    Culiacan, Sinaloa 80000, Mexico
  • Sanatorio CEMSI Chapultepec
    Culiacan, Sinaloa 80040, Mexico
  • Hospital General de Culiacan Dr. Bernardo J. Gastelum
    Culiacan, Sinaloa 80230, Mexico
  • Instituto Medico Panamericano, S.A de C.V.
    Merida, Yucatan 97000, Mexico
  • Unidad Reumatologica Las Americas S.C.P.
    Merida, Yucatan 97000, Mexico
  • Centro Multidisciplinario Para El Desarrollo Especializado De La Investigacion Clinica En
    Merida, Yucatan 97130, Mexico

Showing the first 100 of 153 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6. PubMed 34870800 ↗
  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Nash P, Coates LC, Kivitz AJ, Mease PJ, Gladman DD, Covarrubias-Cobos JA, FitzGerald O, Fleishaker D, Wang C, Wu J, Hsu MA, Menon S, Fallon L, Romero AB, Kanik KS. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. Rheumatol Ther. 2020 Sep;7(3):553-580. doi: 10.1007/s40744-020-00209-4. Epub 2020 Jun 6. PubMed 32506317 ↗
  • Burmester GR, Curtis JR, Yun H, FitzGerald O, Winthrop KL, Azevedo VF, Rigby WFC, Kanik KS, Wang C, Biswas P, Jones T, Palmetto N, Hendrikx T, Menon S, Rojo R. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. Drug Saf. 2020 Apr;43(4):379-392. doi: 10.1007/s40264-020-00904-9. PubMed 32006348 ↗
  • Gladman DD, Charles-Schoeman C, McInnes IB, Veale DJ, Thiers B, Nurmohamed M, Graham D, Wang C, Jones T, Wolk R, DeMasi R. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies. Arthritis Care Res (Hoboken). 2019 Oct;71(10):1387-1395. doi: 10.1002/acr.23930. PubMed 31112005 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in May 2019, 63 months.

Results were first posted in May 2020, 1 year after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 63 months is above that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2013
First posted
Nov 5, 2013
StartActual
Feb 17, 2014
Primary completionActual
May 20, 2019
CompletionActual
May 20, 2019
Results first posted
May 21, 2020
Last update
May 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01976364
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 5, 2013
Start date
Feb 17, 2014
Primary completion
May 20, 2019
Completion
May 20, 2019
Results posted
May 21, 2020
Last update
May 21, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion